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ABSTRACT
A 45-year-old female Jehovah’s Witness patient was diagnosed 
with Lutembacher syndrome, New York Heart Association 
(NYHA) class IV congestive heart failure (CHF), and severe 
malnutrition. An echocardiogram showed a 38 mm diameter 
ostium secundum atrial septal defect with a mitral valve 
area of 0.5  cm² and a Wilkins score of 10. The patient had 
severe pulmonary hypertension at an estimated systolic pres-
sure of 96  mmHg. In addition, the right ventricle presented 
with significant dilation and severe dysfunction, and severe 
tricuspid valve regurgitation was also observed. Despite 
optimal clinical treatment, improvement was not observed in 
the CHF or in the patient’s overall condition, which led to 
a change in the initial surgical treatment plan. A two-stage 
therapy was implemented, starting with a balloon mitral 
valvotomy as a bridge to surgery. The postoperative mitral valve 
area increased to 1.34  cm². The patient showed significant 
clinical improvement, and a mitral valve replacement surgery 
was performed 120 days later with a mechanical valve and 
atrioseptoplasty using a bovine pericardial patch, as well as 
tricuspid valve cerclage. The patient was discharged 11 days 
after the surgery, and is currently in the sixth postoperative 
month. She continues to show clinical stability and improve-
ments in her quality of life.
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Case Report
I n 1916, René Lutembacher
1 was the first to describe 
the combination of mitral stenosis and interatrial 
communication (IAC). The resulting haemodynamic 
repercussion of this association depends on the size 
of the communication and severity of the valvular 
RESUMO
Valvotomia Mitral Percutânea em Paciente  
com Síndrome de Lutembacher como Ponte  
para Intervenção Cirúrgica Definitiva
Paciente com 45 anos de idade, do sexo feminino, testemunha de 
Jeová, portadora de síndrome de Lutembacher, com insuficiência 
cardíaca congestiva (ICC) grau funcional IV da New York Heart 
Association (NYHA) e desnutrição grave. O ecocardiograma 
revelou comunicação interatrial tipo ostium secundum, com 
38 mm de diâmetro; área valva mitral de 0,5 cm², com escore 
de Wilkins de 10; hipertensão pulmonar grave, com pressão 
sistólica estimada em 96 mmHg; ventrículo direito com signifi-
cativa dilatação e disfunção grave; e insuficiência valvar tricús-
pide grave. Apesar do tratamento clínico otimizado, não houve 
melhora do quadro de ICC nem do estado geral, motivando a 
mudança da conduta de tratamento cirúrgico inicial para trata-
mento em dois tempos, primeiramente por meio de valvotomia 
mitral por balão, como ponte para a cirurgia. A área valvar mitral 
pós-procedimento aumentou para 1,34 cm². A paciente evoluiu 
com significativa melhora clínica, sendo realizada cirurgia 120 dias 
após, com substituição da válvula mitral por uma prótese 
mecânica e atriosseptoplastia com patch de pericárdio bovino, 
além de cerclagem da válvula tricúspide. A alta hospitalar ocorreu 
11 dias após a cirurgia. Atualmente, encontra-se no sexto mês 
pós-procedimento cirúrgico, evoluindo com estabilidade clínica 
e melhora da qualidade de vida. 
DESCRITORES: Estenose da valva mitral. Síndrome de Lutem bacher. 
Comunicação interatrial. Hipertensão pulmonar.
stenosis, which can cause varying degrees of pulmo-
nary hypertension, dilation of the right chambers, and 
tricuspid regurgitation. Currently, this condition can 
be treated using percutaneous intervention (balloon 
mitral valvotomy and occlusion of the defect using a 
prosthesis) or a standard surgical treatment.2–7
The case of a patient with a wide ostium secundum 
type IAC associated with mitral stenosis is reported; she 
was admitted in poor general state with New York Heart 
Association (NYHA) class IV severe congestive heart 
failure (CHF) refractory to optimal clinical treatment. 
Performing balloon valvotomy as the initial treatment 
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resulted in haemodynamic and overall improvement of 
her condition, allowing the subsequent surgery to proceed 
with the patient in better condition and at lower risk.
CASE REPORT
The patient had a history of dyspnea on exertion 
since childhood, when she was diagnosed with congenital 
cardiopathy, for which follow-up was recommended. 
She had led a normal life until her second pregnancy 
when, at five months, her gynaecologist referred her to 
a cardiologist. At that time, the patient had developed 
dyspnea on minimal exertion, she felt fullness when 
eating, and she had edema in the lower limbs.
She did not keep a regular follow-up until she 
was referred to the Cardiology Outpatient Clinic at the 
Cardiac Surgery Service of the Hospital Santa Izabel 
da Santa Casa de Misericórdia da Bahia (Salvador, 
BA, Brazil). She was immediately admitted due to her 
precarious state, anaemia, and NYHA class IV CHF. 
A physical exam on admission demonstrated that 
the patient was malnourished, with pale 2+/4+ mucous 
membranes, jugular veins distended at 45 degrees, and 
palpable and filiform peripheral pulses. 
 – Examination of the cardiovascular system showed 
that the precordial region was active with a right 
precordial impulsion. 
 – Upon palpation, the presence of a systolic thrill 
was found on the tricuspid region, and diastolic 
thrill was found on the mitral region. In addition, 
the apex impulse was decreased and palpable 
on the left mid-axillary line, and a second heart 
sound was palpable on the pulmonic region. 
 – Upon auscultation, the heart rate was 100 beats/
minute, with a regular rhythm and accentuation 
of the second heart sound, which presented as 
a fixed splitting. A IV/VI systolic murmur on the 
high left sternal border, a IV/VI diastolic mur-
mur on the mitral region and a IV/VI systolic 
murmur on the tricuspid region that intensified 
with deep inspiration were also observed.
An increased abdominal volume secondary to a 
large ascites was present. On palpation, the liver was 
enlarged and the patient reported pain. Pulmonary aus-
cultation revealed the presence of rales on the inferior 
third of both lungs. The presence of 2+/4+ lower limb 
edema was noticed as well.
An electrocardiogram showed bi-atrial and right 
ventricular enlargement. A chest X-ray showed in-
creased pulmonary flow and an increased heart area 
with predominance of the right chambers and dilation 
of the medium arch.
A transthoracic echocardiogram showed the pres-
ence of a large ostium secundum type IAC measuring 
38 mm, with severe mitral stenosis at a mitral valve area 
of 0.5  cm2 and a Wilkins8 score of 10. Severe pulmo-
nary hypertension with an estimated systolic pressure 
of 96 mmHg, a right ventricle with significant dilation 
and severe dysfunction, an increase in the size of the 
atria, severe tricuspid valve regurgitation, and normal 
left ventricular systolic function with an ejection frac-
tion of 61% (Figure 2) were also observed.
Treatment consisted of absolute bed rest with the 
head of the bed elevated, and optimised pharmacologic 
measures to treat the CHF. A significant improvement 
was not observed despite increasing doses of intrave-
nous furosemide. The case was discussed in a panel 
whose members included her clinician, the intensive 
care unit (ICU) physician, and her surgeon. A two-part 
approach to treatment was selected. Initially, a balloon 
mitral valvotomy would be performed as a palliative 
treatment to relieve the mitral stenosis and improve the 
patient’s haemodynamics and symptoms. Then, definitive 
surgery would be performed.
Balloon mitral valvotomy was preceded by cardiac 
catheterisation, which did not show obstructive coronary 
disease. Dilation was performed with a 26-mm balloon 
catheter using the Inoue technique. The balloon was 
initially inflated to 24  mm, and then a second dila-
tion to 26  mm was performed. Left ventriculography 
after the dilation showed mild mitral regurgitation. The 
procedure was performed without intercurrences. 
The area of the mitral valve was 1.34 cm2 as measured 
on the following day by planimetry (Figure 3).
The development of atrial flutter on the first week 
post-valvotomy required cardioversion, which was suc-
cessful and occurred without intercurrences. Despite the 
suboptimal results from the balloon mitral valvotomy, 
the patient showed progressive improvement after the 
percutaneous intervention. After hospitalisation for 
slightly over two weeks, the patient was discharged 
with NYHA class II and was prescribed iron and folic 
acid supplements to increase haemoglobin levels (under 
Figure 1 – Chest X-ray on admission.
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strict orders from the surgical team) since she refused to 
use blood products during surgery for religious reasons.
The patient was readmitted to the hospital on May 
19, 2011 and underwent mitral valve replacement 
surgery using a St. Jude 29M mechanical prosthesis 
(St. Jude Medical – St. Paul, MN, United States). The 
IAC was closed with a bovine pericardial patch (atrio-
septoplasty), and cerclage of the tricuspid valve was 
performed using the De Vega technique. The patient 
was discharged from the ICU three days after surgery. 
In the infirmary, the patient’s condition continued to 
stabilise, and she was discharged from the hospital 
on May 30, 2011.
DISCUSSION
Lutembacher syndrome is characterised by the 
association of IAC and mitral stenosis. The prevalence 
of this syndrome is uncertain. It is more common in 
females, partly due to the greater incidence of both 
mitral stenosis and IAC in females. Haemodynamic 
repercussions and clinical manifestations of Lutembacher 
syndrome depend on the size of the IAC and on the 
severity of the mitral stenosis.
Currently, Lutembacher syndrome can be treated by 
percutaneous intervention or standard surgery. In very 
experienced centres, and in select cases, percutaneous 
occlusion of IAC using different devices associated 
with balloon mitral valvotomy can be an option. The 
selection criteria for percutaneous intervention are 
the same as those used for the individual diseases. 
Regarding balloon mitral valvotomy, a Wilkins score ≤ 8 
represents a good expectation of immediate results and 
a good prognosis. With respect to the IAC, an ostium 
secundum or oval fossa type can be treated percuta-
neously, for which a defect ≤  35  mm and a ≥  5  mm 
distance of the borders (in its more rigid portion) from 
the coronary sinus, mitral valve, and superior vena cava 
are required. This information can be obtained with a 
transesophageal echocardiogram.
In the present case, because the patient was from 
the Sistema Único de Saúde (Brazilian Unified Health 
System) and did not have medical coverage for IAC 
occluder prosthesis, initial percutaneous treatment was 
not considered. In addition, a Wilkins echocardiographic 
score of 10 was the limiting factor for balloon mitral 
valvotomy. The option for balloon mitral valvotomy 
was determined to be viable after a serious discussion 
among clinical cardiologists, surgeons, and ICU physi-
cians. The initial treatment with high doses of diuretics 
was not effective and did not provide adequate clinical 
control of the patient’s systemic congestion symptoms. 
There was concern that if she remained refractory to 
treatment, she would not survive the surgery due to her 
poor general state and the complications inherent to the 
postoperative period that are experienced by patients 
with right ventricular dysfunction. Her religion was 
another complicating factor, since she was a Jehovah’s 
Witness and refused blood products.
The patient and her family were informed about 
the risks of the proposed procedures, including those 
Figure 2 – Interatrial communication Ostium secundum type and mitral valve stenosis.
Figure 3 – Mitral valvular area after valvotomy.
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inherent to balloon mitral valvotomy. Erythropoietin, iron, 
and folic acid were then administered to progressively 
increase haemoglobin levels, and the administration of 
cardiovascular drugs was maintained.
The success of balloon mitral valvotomy is charac-
terised by an increased valvular area > 25% of the 
initial area and a mitral valvular area ≥  1.5  cm2 in 
the absence of mitral regurgitation >  2+, according 
to angiographic criteria.9,10 The patient had an echo-
cardiographic score of 10, subvalvular stenosis (3), 
thickening (2), mobility (3), and calcification (2). 
On radioscopy, she had a calcification of 2++. The 
suboptimal result obtained with balloon mitral valvotomy, 
with a final mitral valvular area of 1.34  cm2, resulted 
in a significant clinical improvement, and the patient 
was discharged from the hospital with NYHA class II/IV 
CHF. She returned later for surgery with increased 
haematocrit levels as required by the cardiovascular 
surgeon.
Surgery consisted of mitral valve replacement using 
a St. Jude 29M mechanical prosthesis and closure of the 
IAC with a bovine pericardial patch (atrioseptoplasty), 
as well as tricuspid valve cerclage using the De Vega 
technique to correct the tricuspid regurgitation. The 
choice of valvular substitute for atrioventricular orifi-
ces has been the subject of many discussions among 
those who defend biological or mechanical prostheses; 
thrombosis and longevity are the most relevant factors 
in this context. Although biological prostheses have a 
low incidence of thrombosis and do not require anti-
coagulation, they do not last as long as mechanical 
prostheses. In the present report, it was decided to 
use a mechanical prosthesis in order to offer a more 
definitive treatment, which implied the indefinite use 
of anticoagulants.
The postoperative evolution of the patient was 
surprisingly good; she maintained a satisfactory cardiac 
output and stable haemodynamics, and she did not 
experience significant bleeding. She was discharged 
from the hospital 11 days after the surgery.
She is now in the sixth postoperative month. She 
is stable, and her quality of life has improved.
This report confirms the importance of collaborative, 
interdisciplinary work among clinical cardiologists, ICU 
physicians, and cardiovascular surgeons in defining the 
best individual strategy to be used with the devices that 
are available at a particular institution.
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